<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618967</url>
  </required_header>
  <id_info>
    <org_study_id>20140322</org_study_id>
    <nct_id>NCT02618967</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of AMG 570 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain initial information on the safety and tolerability
      (effects good or bad), pharmacokinetics (what the body does to the drug), and
      pharmacodynamics (what the drug does to the body) of a single dose of AMG 570.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2016</start_date>
  <completion_date type="Anticipated">August 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidences of treatment-emergent adverse events.</measure>
    <time_frame>Up to 105 days</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes in physical examinations.</measure>
    <time_frame>Up to 105 days</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes in vital signs.</measure>
    <time_frame>Up to 105 days</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes in laboratory safety tests.</measure>
    <time_frame>Up to 105 days</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes in electrocardiograms (ECGs).</measure>
    <time_frame>Up to 105 days</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter of maximum observed concentration [Cmax].</measure>
    <time_frame>Up to 105 days</time_frame>
    <description>PK Effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of time at Cmax [tmax].</measure>
    <time_frame>Up to 105 days</time_frame>
    <description>PK Effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of area under the concentration-time curve [AUC].</measure>
    <time_frame>Up tp 105 days</time_frame>
    <description>PK Effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Blood Receptor Occupancy Assessments.</measure>
    <time_frame>Up to 105 days</time_frame>
    <description>PD Effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lymphocyte subset counts.</measure>
    <time_frame>Up to 105 days</time_frame>
    <description>PD Effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-AMG 570 binding antibodies.</measure>
    <time_frame>Up to 105 days</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 dose levels of matching AMG 570 placebo administered as single dose subcutaneous in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 570 Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 570</intervention_name>
    <description>6 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.</description>
    <arm_group_label>AMG 570 Arm</arm_group_label>
    <other_name>Active Comparator, Investigational Product, and Study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 570 Matching Placebo</intervention_name>
    <description>6 dose levels of Placebo administered as single dose subcutaneous in healthy volunteers.</description>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>Placebo, Investigational Product, and Study drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by the investigator

          -  Normal or clinically acceptable ECG

          -  Female subjects must be of documented non-reproductive potential

          -  Subjects must be current for all vaccinations

          -  Other inclusion criteria may apply

        Exclusion Criteria:

          -  Current or chronic history of liver disease

          -  History of active infections

          -  History of significant respiratory disorder

          -  Evidence of renal disease

          -  Other exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Safety Study</keyword>
  <keyword>Placebo Control</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

